A health startup aiming to ‘revolutionise’ hormonal and reproductive health has secured multi-million pound investment.
Women’s health specialist Hertility Health has secured £4.2m in seed funding in a round led by investor LocalGlobe.
The round also saw participation from Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.
Founded in 2020 by Dr Helen O’Neill, Dr Natalie Getreu and Deirdre O’Neill, Hertility specialises in reducing diagnosis times for women’s health issues such as endometriosis and PCOS.
Hertility Health CEO and founder, Dr Helen O’Neill, commented: “We live in a society that expects us to tolerate pain and mask our symptoms. Some women spend over ten years on their contraception, never fully knowing if there might be something wrong.”
The investment will help Hertility Health expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing, as well as aid the expansion of its current clinical trials which aim to reduce diagnosis time for conditions.
This funds will also be used to establish Hertility Health as a scientific and clinical educational health hub for women.
Julia Hawkins at LocalGlobe added: “The world class team of experts, scientists and researchers at Hertility Health are what make it a real game-changer in the industry.
“Together, we’re excited to help Hertility Health become the home for women’s health, building on its incredible success to date and meeting the clear consumer demand for an accessible, affordable, high-quality solution to reproductive health concerns and curiosity.”
